09:09 AM EST, 03/04/2025 (MT Newswires) -- PepGen ( PEPG ) said Tuesday it has made a voluntary decision to temporarily pause its CONNECT2-EDO51 phase 2 study of PGN-EDO51 in Duchenne muscular dystrophy patients until it can review results from an ongoing study.

Pausing the study until PepGen ( PEPG ) is able to review results from the 10 mg/kg group in the phase 2 CONNECT1-EDO51 trial "will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2," said James McArthur, CEO of PepGen ( PEPG ).

PepGen ( PEPG ) shares were down 11% in premarket activity Tuesday.